UK’s medicines watchdog recalls five Wockhardt medicines
The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has recalled five medicines made by Indian drugmaker Wockhardt (BSE: WOCK) after deficiencies identified by a recent inspection.
The MHRA asked pharmacies, dispensing clinics and wholesalers to return five drugs in a variety of strengths. Most of the medicines affected are used for pain relief but it also includes one used to treat type 2 diabetes (Gliclazide). This follows a precautionary recall by Wockhardt over five medicines made at its manufacturing site in Chikalthana, India.
The affected products are in most cases available from alternative manufacturers and the Department of Health will ensure that patients can get their medicines when they need them.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze